Literature DB >> 10559355

Dynamin is required for recombinant adeno-associated virus type 2 infection.

D Duan1, Q Li, A W Kao, Y Yue, J E Pessin, J F Engelhardt.   

Abstract

Recombinant adeno-associated virus (rAAV) vectors for gene therapy of inherited disorders have demonstrated considerable potential for molecular medicine. Recent identification of the viral receptor and coreceptors for AAV type 2 (AAV-2) has begun to explain why certain organs may demonstrate higher efficiencies of gene transfer with this vector. However, the mechanisms by which AAV-2 enters cells remain unknown. In the present report, we have examined whether the endocytic pathways of rAAV-2 are dependent on dynamin, a GTPase protein involved in clathrin-mediated internalization of receptors and their ligands from the plasma membrane. Using a recombinant adenovirus expressing a dominant-inhibitory form of dynamin I (K44A), we have demonstrated that rAAV-2 infection is partially dependent on dynamin function. Overexpression of mutant dynamin I significantly inhibited AAV-2 internalization and gene delivery, but not viral binding. Furthermore, colocalization of rAAV and transferrin in the same endosomal compartment provides additional evidence that clathrin-coated pits are the predominant pathway for endocytosis of AAV-2 in HeLa cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10559355      PMCID: PMC113092     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

Review 1.  The structural era of endocytosis.

Authors:  M Marsh; H T McMahon
Journal:  Science       Date:  1999-07-09       Impact factor: 47.728

2.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

Review 3.  Endocytosis and molecular sorting.

Authors:  I Mellman
Journal:  Annu Rev Cell Dev Biol       Date:  1996       Impact factor: 13.827

Review 4.  The dynamins: redundant or distinct functions for an expanding family of related GTPases?

Authors:  R Urrutia; J R Henley; T Cook; M A McNiven
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

5.  Control of EGF receptor signaling by clathrin-mediated endocytosis.

Authors:  A V Vieira; C Lamaze; S L Schmid
Journal:  Science       Date:  1996-12-20       Impact factor: 47.728

6.  Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis.

Authors:  K J Fisher; G P Gao; M D Weitzman; R DeMatteo; J F Burda; J M Wilson
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

7.  Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain.

Authors:  M G Kaplitt; P Leone; R J Samulski; X Xiao; D W Pfaff; K L O'Malley; M J During
Journal:  Nat Genet       Date:  1994-10       Impact factor: 38.330

8.  Adeno-associated virus type 2 binds to a 150-kilodalton cell membrane glycoprotein.

Authors:  H Mizukami; N S Young; K E Brown
Journal:  Virology       Date:  1996-03-01       Impact factor: 3.616

9.  Induction of mutant dynamin specifically blocks endocytic coated vesicle formation.

Authors:  H Damke; T Baba; D E Warnock; S L Schmid
Journal:  J Cell Biol       Date:  1994-11       Impact factor: 10.539

10.  Mutations in human dynamin block an intermediate stage in coated vesicle formation.

Authors:  A M van der Bliek; T E Redelmeier; H Damke; E J Tisdale; E M Meyerowitz; S L Schmid
Journal:  J Cell Biol       Date:  1993-08       Impact factor: 10.539

View more
  72 in total

1.  Adeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction efficiency in murine fibroblasts.

Authors:  J Hansen; K Qing; A Srivastava
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 2.  Pathways of cell infection by parvoviruses and adeno-associated viruses.

Authors:  Maija Vihinen-Ranta; Sanna Suikkanen; Colin R Parrish
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

3.  Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups.

Authors:  Joseph E Rabinowitz; Dawn E Bowles; Susan M Faust; Julie G Ledford; Scott E Cunningham; R Jude Samulski
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 4.  Adeno-associated Virus as a Mammalian DNA Vector.

Authors:  Max Salganik; Matthew L Hirsch; Richard Jude Samulski
Journal:  Microbiol Spectr       Date:  2015-08

5.  rAAV2 traffics through both the late and the recycling endosomes in a dose-dependent fashion.

Authors:  Wei Ding; Liang N Zhang; Charles Yeaman; John F Engelhardt
Journal:  Mol Ther       Date:  2006-01-25       Impact factor: 11.454

Review 6.  Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.

Authors:  Jane T Seto; Julian N Ramos; Lindsey Muir; Jeffrey S Chamberlain; Guy L Odom
Journal:  Curr Gene Ther       Date:  2012-06       Impact factor: 4.391

Review 7.  Adeno-associated virus vectors: potential applications for cancer gene therapy.

Authors:  Chengwen Li; Dawn E Bowles; Terry van Dyke; Richard Jude Samulski
Journal:  Cancer Gene Ther       Date:  2005-12       Impact factor: 5.987

8.  Effect of inhibition of dynein function and microtubule-altering drugs on AAV2 transduction.

Authors:  Sachiko Hirosue; Karin Senn; Nathalie Clément; Mathieu Nonnenmacher; Laure Gigout; R Michael Linden; Thomas Weber
Journal:  Virology       Date:  2007-06-22       Impact factor: 3.616

9.  Adeno-associated virus capsid antigen presentation is dependent on endosomal escape.

Authors:  Chengwen Li; Yi He; Sarah Nicolson; Matt Hirsch; Marc S Weinberg; Ping Zhang; Tal Kafri; R Jude Samulski
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

Review 10.  Gene therapy using adeno-associated virus vectors.

Authors:  Shyam Daya; Kenneth I Berns
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.